ClinicalTrials.Veeva

Menu

Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

Albert Einstein College of Medicine logo

Albert Einstein College of Medicine

Status

Enrolling

Conditions

DiGeorge Syndrome
22q11.2 Deletion Syndrome

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT00556530
R01HL157157 (U.S. NIH Grant/Contract)
R01HL084410 (U.S. NIH Grant/Contract)
1999-201

Details and patient eligibility

About

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

Full description

22q11.2 deletion syndrome is a disorder caused by the deletion of a small piece of chromosome 22. Most people with this disorder are missing a sequence of about 3 million DNA building blocks on chromosome 22 within each cell. This disorder affects many areas of the body. People with 22q11.2 deletion syndrome may have heart defects, immune deficiency, kidney abnormalities, hearing loss, and cleft palate or other facial deformities. Many children experience developmental delays and learning disabilities, and they have an increased risk of developing mental illnesses, including schizophrenia, depression, anxiety, and bipolar disorder. All people with 22q11.2 deletion syndrome are missing the same sequence of DNA, but the severity of this disorder varies widely; some people are diagnosed with multiple health and developmental problems, while others experience very few symptoms. In some people, the symptoms may be so minimal that they are not even aware they have 22q11.2 deletion syndrome. This study will examine genetic material-either from blood or saliva-among people with 22q11.2 deletion syndrome. Participants will attend one study visit and undergo either blood or saliva collection. By analyzing the DNA sequences of participants, the study will aim to identify any genetic variations that may affect the severity of 22q11.2 deletion syndrome.

NOTE: Each clinical site is under the governance of its own Institutional Review Board and discretionary clinicaltrials.gov registration.

Enrollment

1,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has 22q11 deletion of 3 megabases (Mb)

Exclusion criteria

  • Has 22q11 deletion smaller than 3 Mb or no deletion

Trial contacts and locations

1

Loading...

Central trial contact

Bernice E. Morrow, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems